

Nymox up 45% since recent prostrate cancer result news

Nymox Pharmaceutical (Nasdaq: NYMX) stock has climbed nearly 45% in the last 8 trading days.

The reason is the recent announcement of their prostrate cancer study results.

Nymox Pharmaceutical (Nasdaq: NYMX) stock climbed nearly 45% in under two weeks after their recent new release.

The company recently reported long-term prostate cancer results in 7 year prospective study of 995 middle-aged and elderly men without cancer in the US.

The trial showed the men who received fexapotide had a major reduction in incidence of prostate cancer.

To read the full press release, click [HERE](#)